Harvard Bioscience Inc (HBIO) Annual Income Statement (USD)
HBIO Quarterly Financials (USD)
Frequently Asked Questions About Harvard Bioscience Inc (HBIO) Stock
Harvard Bioscience Inc's (HBIO) last reported annual revenue was USD 112.25 Million.
Harvard Bioscience Inc's (HBIO) annual revenue growth rate based on the revenue reported in the past 5 years is : -1.45%
Harvard Bioscience Inc's(HBIO) is not profitable as of its last reported annual financials.
The net profit margin for Harvard Bioscience Inc's(HBIO) from its laster reported year is -3.04%
The return on equity (ROE) for Harvard Bioscience Inc's(HBIO) from its last reported annual financials is : -4.70%
The return on assets (ROA) for Harvard Bioscience Inc's(HBIO) from its last reported annual financials is : 1.10%
The return on invested capital (ROIC) for Harvard Bioscience Inc's(HBIO) from its last reported annual financials is : 1.25%
The Debt to Equity ratio for Harvard Bioscience Inc's(HBIO) from its last reported annual financials is : 42.02%
The dividend yield for Harvard Bioscience Inc's(HBIO) from its laster reported year is 0.00%
Harvard Bioscience Inc's(HBIO) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HBIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
